<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705430</url>
  </required_header>
  <id_info>
    <org_study_id>0248-15-RMC</org_study_id>
    <nct_id>NCT02705430</nct_id>
  </id_info>
  <brief_title>Effect of EPA-DHA Supplement, Life Style Modification Standard Treatment on Clinical Outcome Lipid Membrane Composition in Type 2 Diabetes</brief_title>
  <official_title>Effect of EPA-DHA Supplementation, Life Style Modification or Standard Treatment on Clinical Outcome and Lipid Membrane Composition in Type 2 Diabetic Patients: a 3 Months Perspective Randomized Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is: to examine some of the mechanisms by which a change in life
      style alone or supplemented with a diet supplemented in n-3 PUFA, and associated with this
      computerized life style regulation reduces the development of diabetic complication in a
      small population based study.

      (The NewMe™ / Eco-fusion, Ltd is a science-driven lifestyle change program for better living
      -www.eco-fusion.com)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c &lt; 7%</measure>
    <time_frame>3 months</time_frame>
    <description>To attain individualized HbA1c &lt; 7% goal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in hypoglycaemic drugs (type and dose),</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure&lt; 140\80 mmHg</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile. LDL cholesterol ,100 mg/dL; triglycerides ,150 mg/dL; HDL cholesterol .40 mg/dL for men; HDL cholesterol .50 mg/dL for women.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid membrane fatty acid composition analysis</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group A will continue their actual therapy (control).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA and DHA capsules of 2 g/day</intervention_name>
    <description>EPA and DHA capsules of 2 g/day</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress management phone application (Eco Fusion Mentally)</intervention_name>
    <description>Stress management phone application (Eco Fusion Mentally)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>life style program using a mobile phone (Eco Mentally and NewMe)</intervention_name>
    <description>life style program using a mobile phone (Eco Mentally and NewMe)</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mobile phone</intervention_name>
    <description>mobile phone</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants between 18-80 years of age.

          2. Have been diagnosed with type 2 diabetes more than nine months before study entry,
             and, despite having been given standard dietary advice by dietitian, doctor, or nurse
             and prescribed oral hypoglycaemic agents, insulin, or both.

          3. Have persistent unsatisfactory glycaemic control defined as HbA1c more than 7%.

          4. Participants should have at least two of the following three characteristics:

               1. Overweight or obesity (body mass index ≥25),

               2. Hypertension (currently prescribed antihypertensive drugs or blood pressure
                  &gt;140/90 mm Hg despite optimized antihypertensive drug treatment),

               3. Dyslipidaemia (currently prescribed lipid modifying drugs) or one or more of:

               1. total cholesterol &gt;5.2 mmol/l,

               2. low density lipoprotein cholesterol &gt;3.5 mmol/l,

               3. triglycerides &gt;2.0 mmol/l,

               4. high density lipoprotein cholesterol &lt;1.0 mmol/l (despite optimised lipid
                  modifying drug treatment).

        Exclusion Criteria:

          1. Pregnancy

          2. Serious chronic illness.e.g cancer

          3. End stage renal failure

          4. Amputation

          5. Stroke

          6. Severe retinal microangiopathy

          7. Pancreas transplantation

          8. HbA1c &lt;7%

          9. Requires diet only treatment

         10. They are too busy with work
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Singer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of General Intensive care unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Singer, Professor</last_name>
    <phone>+972-3-9376521</phone>
    <email>psinger@clalit.org.il</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Pierre Singer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

